ReShape Lifesciences
Yahoo Finance • last year
ReShape Lifesciences® Enters into Warrant Exercise Transaction for $1.2 Million in Gross Proceeds
IRVINE, Calif., Nov. 21, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences, Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, announced today that it has entered into a warrant exercise agreem... Full story
Yahoo Finance • last year
ReShape Lifesciences® Reports Third Quarter Ended September 30, 2023 Financial Results and 2024 Cost Reduction Plan
Third Quarter Core Operating Expenses Reduced 37% Compared to Third Quarter of 2022 Cost Reduction Plan To Reduce Operating Expenses In 2024 by Over 40% Compared to 2023 Conference Call to be Held at 5:00 pm ET Today IRVINE, Calif., Nov... Full story
Yahoo Finance • last year
ReShape Lifesciences® to Announce Financial Results for the Third Quarter Ended September 30, 2023 and Provide Corporate Update
IRVINE, Calif., Nov. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will report its financial results for the t... Full story
Yahoo Finance • last year
ReShape Lifesciences® Announces Pricing of $3.0 Million Public Offering
IRVINE, Calif., Sept. 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its public offering of 9,100,000 units,... Full story
Yahoo Finance • last year
ReShape Lifesciences® Announces Participation in the LD Micro Main Event XVI
IRVINE, Calif., Sept. 22, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that Paul F. Hickey, President and Chief Executive... Full story
Yahoo Finance • last year
ReShape Lifesciences® Significantly Strengthens Patent Portfolio Related to its Obalon® Balloon System
IRVINE, Calif., Sept. 19, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has significantly strengthened the pa... Full story
Yahoo Finance • last year
ReShape Lifesciences® Receives NIH SBIR Grant to Further Develop Proprietary Diabetes Bloc-Stim Neuromodulation™ Device
IRVINE, Calif., Sept. 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the Company was awarded a $331,541 Small Business... Full story
Yahoo Finance • last year
ReShape Lifesciences® Signs Preferred Partner Agreement With Hive Medical for Lead Optimization Software
IRVINE, Calif., June 29, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the signing of a preferred partner agreement with H... Full story
Yahoo Finance • last year
ReShape Lifesciences® Presents Data on its Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at the ASMBS 2023 Annual Meeting
IRVINE, Calif., June 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today presented data on its proprietary Diabetes Bloc-Stim Neuromod... Full story
Yahoo Finance • last year
ReShape Lifesciences® Submits FDA PMA Supplement Application for the Next-Generation Lap-Band® 2.0
IRVINE, Calif., June 26, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences® (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the submission of a Premarket Approval (PMA) supplement... Full story
Yahoo Finance • last year
ReShape Lifesciences® to Participate in Investor and Industry Conferences in June
SAN CLEMENTE, Calif., June 14, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced participation in the following investor and i... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences® Reports First Quarter Ended March 31, 2023 Financial Results and Provides Corporate Update
Achieved Continued Improvement in Operational Effectiveness With First Quarter 2023 Operating Expenses Down 42.9% Compared to the First Quarter of 2022 Executing a Plan For Growth and Profitability With a Balance Sheet Bolstered By Approx... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences Announces Pricing of $2.5 Million Registered Direct Offering and Concurrent Private Placement Priced At-The-Market
SAN CLEMENTE, Calif., April 20, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purcha... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences® Receives Notice of Allowance for U.S. Patent Related to its Obalon® Balloon System
SAN CLEMENTE, Calif., April 11, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that the company has received a Notice of Allowa... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences® To Delay Year Ended December 31, 2022 Earnings Release and Conference Call
SAN CLEMENTE, Calif., March 28, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today announced that it will delay its year ended December 3... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences Announces Closing of Upsized $10.2 Million Underwritten Public Offering
SAN CLEMENTE, Calif., Feb. 08, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the closing of its upsized underwritten publi... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences Announces Pricing of Upsized $10.2 Million Underwritten Public Offering
SAN CLEMENTE, Calif., Feb. 06, 2023 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the pricing of its upsized underwritten publi... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences™ Reports Third Quarter 2022 Financial Results and Provides Corporate Update
SAN CLEMENTE, Calif., Nov. 14, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health-solutions company, today reported financial and operating results for the third... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences Announces $750,000 Registered Direct Offering
SAN CLEMENTE, Calif., Nov. 08, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences Inc. (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced that it has entered into a securities purchas... Full story
Yahoo Finance • 2 years ago
ReShape Lifesciences™ Presents Data on Proprietary Diabetes Bloc-Stim Neuromodulation™ Device at ObesityWeek®
SAN CLEMENTE, Calif., Nov. 03, 2022 (GLOBE NEWSWIRE) -- ReShape Lifesciences™ (Nasdaq: RSLS), the premier physician-led weight loss and metabolic health solutions company, today announced the presentation of data on its proprietary Diabe... Full story
